文章基本信息
- 标题：Long-term Therapeutic Effect of Intravitreal Bevacizumab (Avastin) on Myopic Choroidal Neovascularization
- 本地全文：下载
- 作者：Seo, Young Seung ; Chang, Moo Hwan
- 期刊名称：Journal of the Korean Ophthalmological Society
- 印刷版ISSN：0378-6471
- 出版年度：2011
- 卷号：52
- 期号：1
- 页码：34-40
- DOI：10.3341/jkos.2011.52.1.34
- 语种：Korean
- 出版社：The Korean Ophthalmological Society
- 摘要：Purpose
To evaluate the long-term therapeutic effects of intravitreal bevacizumab on myopic choroidal neovascularization (CNV).
MethodsMedical records of 6 patients who underwent intravitreal bevacizumab injection for myopic CNV and were followed for more than 2 years, were retrospectively investigated. The best corrected visual acuity was compared at 1,3,12, and 24 months after injection. Two years after the injection, a fluorescein angiography and optical coherence tomography (OCT) were performed to evaluate the central macular thickness and leakage of CNV.
ResultsThe mean best corrected visual acuity was 1.16 ± 0.43 (logMAR), 0.45 ± 0.21 (logMAR), 0.29 ± 0.23 (logMAR), 0.14 ± 0.11 (logMAR), and 0.11 ± 0.06 (logMAR) at baseline, 1, 3, 12, and 24 months after injection, respectively.
The average number of injections was 1.33. In OCT, 2 years after bevacizumab injection, central foveal thickness was significantly decreased as compared to the baseline, and fluorescein angiography showed no leakage of fluorescein.
ConclusionsIntravitreal bevacizumab injection for the treatment of myopic CNV was effective in maintaining postoperative visual acuity for 2 years.
- 关键词：Bevacizumab; Choroidal neovascularization; Intravitreal injection; Long-term; Myopic CNV
